Literature DB >> 17687099

Exacerbations in cystic fibrosis: 2 . prevention.

Scott C Bell1, Philip J Robinson.   

Abstract

The life span of people with cystic fibrosis (CF) has increased dramatically over the past 50 years. Many factors have contributed to this improvement. Respiratory exacerbations of CF lung disease are associated with the need for hospitalisation and antibiotic treatment, reduction in the quality of life, fragmented sleep and mortality. A number of preventive treatment strategies have been developed to reduce the frequency and severity of respiratory exacerbations in CF including mucolytic agents, physiotherapy and exercise, antibiotics, nutritional strategies, anti-inflammatory treatments and vaccinations against common respiratory pathogens. The evidence for each of these treatments and their potential impact is discussed.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17687099      PMCID: PMC2117269          DOI: 10.1136/thx.2006.060897

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  111 in total

Review 1.  Chest physiotherapy compared to no chest physiotherapy for cystic fibrosis.

Authors:  C van der Schans; A Prasad; E Main
Journal:  Cochrane Database Syst Rev       Date:  2000

2.  Modelling survival in cystic fibrosis.

Authors:  M Corey
Journal:  Thorax       Date:  2001-10       Impact factor: 9.139

3.  Predictive 5-year survivorship model of cystic fibrosis.

Authors:  T G Liou; F R Adler; S C Fitzsimmons; B C Cahill; J R Hibbs; B C Marshall
Journal:  Am J Epidemiol       Date:  2001-02-15       Impact factor: 4.897

4.  Infection with Burkholderia cepacia in cystic fibrosis: outcome following lung transplantation.

Authors:  C Chaparro; J Maurer; C Gutierrez; M Krajden; C Chan; T Winton; S Keshavjee; M Scavuzzo; E Tullis; M Hutcheon; S Kesten
Journal:  Am J Respir Crit Care Med       Date:  2001-01       Impact factor: 21.405

Review 5.  Inhaled corticosteroids for cystic fibrosis.

Authors:  C Dezateux; S Walters; I Balfour-Lynn
Journal:  Cochrane Database Syst Rev       Date:  2000

Review 6.  Vaccines for preventing influenza in people with cystic fibrosis.

Authors:  A Tan; P Bhalla; R Smyth
Journal:  Cochrane Database Syst Rev       Date:  2000

Review 7.  Oral non-steroidal anti-inflammatory drug therapy for cystic fibrosis.

Authors:  C Dezateux; A Crighton
Journal:  Cochrane Database Syst Rev       Date:  2000

8.  Effect of continuous antistaphylococcal therapy on the rate of P. aeruginosa acquisition in patients with cystic fibrosis.

Authors:  F Ratjen; G Comes; K Paul; H G Posselt; T O Wagner; K Harms
Journal:  Pediatr Pulmonol       Date:  2001-01

9.  Longitudinal relationship among growth, nutritional status, and pulmonary function in children with cystic fibrosis: analysis of the Cystic Fibrosis Foundation National CF Patient Registry.

Authors:  B S Zemel; A F Jawad; S FitzSimmons; V A Stallings
Journal:  J Pediatr       Date:  2000-09       Impact factor: 4.406

10.  A case-controlled study with dornase alfa to evaluate impact on disease progression over a 4-year period.

Authors:  P L Shah; S Conway; S F Scott; M Rainisio; M Wildman; D Stableforth; M E Hodson
Journal:  Respiration       Date:  2001       Impact factor: 3.580

View more
  12 in total

1.  Pulmonary exacerbations in cystic fibrosis and bronchiectasis.

Authors:  J S Elborn; S C Bell
Journal:  Thorax       Date:  2007-04       Impact factor: 9.139

2.  Palivizumab, pneumococcal and influenza vaccination in cystic fibrosis.

Authors:  Mukta Jain; Anne H Thomson
Journal:  J R Soc Med       Date:  2009-07       Impact factor: 5.344

3.  Life-space mobility is associated with frequency of hospitalization in adults with cystic fibrosis.

Authors:  Eric Raphael Gottlieb; Elisabeth Christine Smith; Linda Lucetta Wolfenden; Richard Mark Allman; Vin Tangpricha
Journal:  Clin Respir J       Date:  2010-10-01       Impact factor: 2.570

4.  Toward implementation of quorum sensing autoinducers as biomarkers for infectious disease states.

Authors:  Anjali K Struss; Ashlee Nunes; Jill Waalen; Colin A Lowery; Prasanna Pullanikat; Judith R Denery; Douglas J Conrad; Gunnar F Kaufmann; Kim D Janda
Journal:  Anal Chem       Date:  2013-02-26       Impact factor: 6.986

Review 5.  Airway epithelial control of Pseudomonas aeruginosa infection in cystic fibrosis.

Authors:  Victoria L Campodónico; Mihaela Gadjeva; Catherine Paradis-Bleau; Ahmet Uluer; Gerald B Pier
Journal:  Trends Mol Med       Date:  2008-02-11       Impact factor: 11.951

6.  Inhaled hypertonic saline in adults hospitalised for exacerbation of cystic fibrosis lung disease: a retrospective study.

Authors:  Alejandro A Pezzulo; David A Stoltz; Douglas B Hornick; Lakshmi Durairaj
Journal:  BMJ Open       Date:  2012-04-19       Impact factor: 2.692

Review 7.  Pseudomonas aeruginosa infection in patients with cystic fibrosis: scientific evidence regarding clinical impact, diagnosis, and treatment.

Authors:  Luiz Vicente Ribeiro Ferreira da Silva Filho; Flavia de Aguiar Ferreira; Francisco José Caldeira Reis; Murilo Carlos Amorim de Britto; Carlos Emilio Levy; Otavio Clark; José Dirceu Ribeiro
Journal:  J Bras Pneumol       Date:  2013 Jun-Aug       Impact factor: 2.624

8.  Early detection of pulmonary exacerbations in children with Cystic Fibrosis by electronic home monitoring of symptoms and lung function.

Authors:  Marieke van Horck; Bjorn Winkens; Geertjan Wesseling; Dillys van Vliet; Kim van de Kant; Sanne Vaassen; Karin de Winter-de Groot; Ilja de Vreede; Quirijn Jöbsis; Edward Dompeling
Journal:  Sci Rep       Date:  2017-09-27       Impact factor: 4.379

Review 9.  Quantification of Phenotypic Variability of Lung Disease in Children with Cystic Fibrosis.

Authors:  Mirjam Stahl; Eva Steinke; Marcus A Mall
Journal:  Genes (Basel)       Date:  2021-05-25       Impact factor: 4.096

10.  Role of C-reactive protein as a biomarker for prediction of the severity of pulmonary exacerbations in patients with cystic fibrosis.

Authors:  Rosa Maria Girón-Moreno; José L Justicia; Sara Yamamoto; Claudia Valenzuela; Carolina Cisneros; Rosa Mar Gómez-Punter; Gilda Fernandes-Vasconcelos; Julio Ancochea
Journal:  BMC Pulm Med       Date:  2014-09-23       Impact factor: 3.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.